IL17A and Miyoshi myopathy: Additionally, the functional inhibition of the CD28/CD80/CD86 axis with CTLA4Ig as well as the use of anti-IL17 mAbs are currently being explored clinically for the treatment of MM patients (Figure 1) [19,54,55].